RxDoctor Payments Data

Douglas Adkisson, MD

Hospitalist · Greeneville, TNNPI 1902953896

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 40.5% of the total. Among hospitalist clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,807in general payments, 2019–2025

Across 122 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$731
  • Novartis$446
  • AstraZeneca$260
  • Abbott$80
  • E.r. Squibb & Sons, L.L.C.$78
  • Inspire Medical Systems, Inc.$42
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$1,71495%
  • Education$945%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,807 in reported general payments places this provider in the 90th percentile of 349 hospitalist providers in Tennessee.

See all hospitalist providers in Tennessee

Medicare billing

Part B allowed, 2024
$203,696
Medicare patients
1,145
Services billed
2,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$279,249
EntrestoSacubitril/Valsartan120$110,073
Repatha SureclickEvolocumab113$86,865
XareltoRivaroxaban100$85,354
Ranolazine ErRanolazine310$31,447
MultaqDronedarone Hcl17$25,343
BrilintaTicagrelor20$14,230
FarxigaDapagliflozin Propanediol19$14,019
Praluent PenAlirocumab23$12,342
Clonidine45$9,164
Icosapent Ethyl15$6,493
Metoprolol Succinate427$6,154
Potassium Chloride229$5,669
Nebivolol Hcl77$5,362
Rosuvastatin Calcium337$4,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$279,249296 claims
NovartisEntresto$446$110,073120 claims
Johnson & JohnsonXarelto$40$85,354100 claims
AstraZenecaBrilinta, Farxiga$260$28,24939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 349 hospitalist providers in Tennessee.

Other hospitalist in Greeneville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →